Choosing treatment options for patients with relapsed/refractory multiple myeloma.
about
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study.Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma.
P2860
Choosing treatment options for patients with relapsed/refractory multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Choosing treatment options for patients with relapsed/refractory multiple myeloma.
@en
type
label
Choosing treatment options for patients with relapsed/refractory multiple myeloma.
@en
prefLabel
Choosing treatment options for patients with relapsed/refractory multiple myeloma.
@en
P2860
P50
P1476
Choosing treatment options for patients with relapsed/refractory multiple myeloma.
@en
P2093
Agnese Losurdo
Roberto Castelli
P2860
P304
P356
10.1586/14737140.2014.863153
P577
2013-12-13T00:00:00Z